Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gut microbiota and intestinal epithelial barrier represent a complex biological system rather than a single molecular target. This interface consists of a diverse community of trillions of microorganisms (microbiota) and a physical layer of epithelial cells reinforced by tight junction proteins that separate the host's internal environment from the external luminal contents (Nature Reviews Gastroenterology & Hepatology, 2019). The microbiota plays a critical role in maintaining barrier integrity by producing metabolites like short-chain fatty acids (SCFAs), which serve as the primary energy source for colonocytes and stimulate the production of antimicrobial peptides (Frontiers in Microbiology, 2021). Conversely, the epithelial barrier prevents the translocation of commensal and pathogenic bacteria into the systemic circulation, thereby preventing chronic inflammation. Dysfunction of this system, often referred to as increased intestinal permeability or "leaky gut," is a hallmark of various gastrointestinal and systemic diseases, including Inflammatory Bowel Disease (IBD) and metabolic syndrome (Cell Host & Microbe, 2020). Therapeutic interventions focus on restoring this balance through probiotics, prebiotics, and postbiotics, or by directly targeting the tight junction assembly with agents like larazotide acetate (Journal of Clinical Investigation, 2018). While not a single receptor or enzyme, the gut-barrier axis is a major focus of drug development for its ability to modulate systemic immunity and metabolic health through the regulation of microbial-host crosstalk.
Modulation of microbial composition to reduce pathobionts, enhancement of tight junction protein expression (e.g., zonula occludens-1, occludin), production of short-chain fatty acids (SCFAs) to provide energy for colonocytes, and regulation of mucosal immune cell activity to maintain tolerance.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut microbiota and intestinal epithelial barrier.